This month several new drugs were introduced on the Canadian market:
TALVEY – talquetamab is a humanized monoclonal antibody used for the treatment of multiple myeloma.
VYLOY – zolbetuximab is a monoclonal antibody used for the treatment of gastric cancer.
ZILBRYSQ – zilucoplan is a medication used for the treatment of generalized myasthenia gravis.
FABHALTA – iptacopan is a medication used for the treatment of paroxysmal nocturnal hemoglobinuria and proteinuria.
CLOROTEKAL – chloroprocaine is a local anesthetic given by injection.
The following drugs were discontinued:
- adefovir (Hepsera)
- enfuvirtide (Fuzeon)
- pralsetinib (Gavreto)
- iothalamate (Conray)